Nuvo Pharmaceuticals Inc (MRVFF) Exchange: OTCQX

Nuvo Research Inc., a specialty pharmaceutical company, researches, develops, and commercializes pharmaceutical products in Europe, Asia, and South America. The company has four commercialized products; a pipeline of topical and transdermal products focusing on various therapeutic areas, including pain and dermatology; and multiple drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. Its topical pain products include Pennsaid, a non-steroidal anti-inflammatory drug that is used for the treatment of the pain of knee osteoarthritis; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of pain of knee osteoarthritis; and Pliaglis, a topical local anaesthetic cream, which provides local dermal anaesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal, as well as heated lidocaine/tetracaine patch, a topical patch that provides local dermal analgesia for superficial venous access and superficial dermatological procedures. The company’s immunology products comprise WF10, an immune system modulating drug containing chlorite and chlorate ions; and Oxoferin, a topical wound healing agent containing the active ingredient in WF10 at a lower concentration. The company was formerly known as Dimethaid Research Inc. and changed its name to Nuvo Research Inc. in September 2005. The company was founded in 1983 and is based in Mississauga, Canada.